Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumours

NCT05255484 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

24

Enrollment

INDUSTRY

Sponsor class

Stopped Completed primary objective.

Conditions

Advanced Solid Tumor

Interventions

DRUG: LM-108
DRUG: An Anti-PD-1 Antibody

Sponsor

LaNova Medicines Limited